SCHEDULE: Sirenia Capital Management Reports 4.3% Stake in Immunome Inc.

Sirenia Capital Management LP and Alex Silverstein have reported beneficial ownership of 4.3% of Immunome Inc.'s common stock as of June 30, 2026.

Summary

• Sirenia Capital Management LP and Alex Silverstein have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Immunome Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially own 4,832,279 shares, representing 4.3% of the outstanding common stock.
• This ownership percentage is calculated based on 113,250,394 shares outstanding as of May 7, 2026, as reported in Immunome's Form 10-Q filed on May 5, 2026.
• Sirenia Capital Management LP is a Delaware limited partnership, and Alex Silverstein is a U.S. citizen and the managing member of Sirenia's general partner.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• Reporting persons hold a significant minority stake (4.3%) in Immunome Inc., indicating investor interest.
• The filing confirms that the shares were acquired and are held in the ordinary course of business, suggesting a non-activist investment approach.

Negatives

• No new financial performance data or strategic updates are provided in this filing.
• The filing does not offer any forward-looking statements or guidance.

Risks

• Potential for increased scrutiny from regulatory bodies due to the reporting of beneficial ownership.
• Market perception could be influenced by the reporting persons' investment strategy and future actions.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating significant stakes in public companies. This filing indicates Sirenia Capital Management's interest in Immunome Inc. within the biotechnology sector, a field often characterized by significant investment and potential for growth or volatility.

Stakeholder Impact

• Shareholders: May observe increased investor interest and potential for future market activity related to Sirenia's stake.
• Management of Immunome Inc.: May be aware of a significant institutional investor's holdings and potential influence.

Next Steps

• Monitoring of Immunome Inc.'s performance and strategic developments by Sirenia Capital Management.
• Potential future filings by Sirenia Capital Management if their ownership stake changes significantly.

Key Dates

Keywords

Immunome Inc., Schedule 13G, Beneficial Ownership, Sirenia Capital Management, Alex Silverstein, Investment Funds, Managed Account, Common Stock